Juzina

Sitagliptin, the active ingredient in Juzina, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It helps control blood glucose in adults with type 2 diabetes mellitus.

GNH USA supplies Juzina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sitagliptin is indicated for glycaemic management in the type 2 diabetes mellitus therapeutic pathway.

Type 2 diabetes mellitus: improves glycaemic control as part of oral antidiabetic therapy, alone or in combination with other agents.

Sitagliptin may be associated with a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient cranial pain. - Upper respiratory tract infection: cough, sore throat, or congestion. - Nausea: occasional feeling of stomach upset. - Diarrhoea: loose stools. - Abdominal pain: mild discomfort in the stomach area.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: including angioedema, anaphylaxis, or Stevens‑Johnson syndrome. - Joint pain: acute, severe arthralgia. - Hepatic injury: marked elevation of liver enzymes. - Hypersensitivity reactions: rash, fever, eosinophilia. - Bullous pemphigoid: rare blistering skin disorder.

When prescribing sitagliptin, clinicians should consider several precautionary measures to ensure safe use. - Renal function: assess baseline kidney function and adjust dose in moderate to severe impairment. - Pancreatitis history: evaluate for prior episodes and discontinue if symptoms develop. - Hypersensitivity: monitor for signs of allergic reaction, especially skin rash or swelling. - Elderly patients: use with caution due to potential comorbidities and polypharmacy. - Concomitant medications: review for drugs that may affect glucose levels or renal clearance. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Sitagliptin can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Insulin or sulfonylureas: combined use may increase risk of hypoglycaemia; dose adjustments are required. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): can raise sitagliptin plasma concentrations, increasing adverse effect risk.

Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism and may reduce sitagliptin exposure, potentially diminishing glucose‑lowering effect. - Diuretics: may affect glycaemic control; monitor blood glucose. - ACE inhibitors or ARBs: observe renal function and potassium levels when used together. - Anticoagulants: monitor INR as glycaemic changes can influence anticoagulation.